SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Covalent Group Inc (CVGR) an undiscovered CRO

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JanyBlueEyes who wrote (90)2/2/2000 3:11:00 PM
From: JanyBlueEyes  Read Replies (1) of 107
 
News - Donald C. Holdsworth to BOD

Covalent Group, Inc. Appoints Marketing Executive to Board of Directors

WAYNE, Pa., Feb. 2 /PRNewswire/ -- Covalent Group, Inc. (Nasdaq: CVGR) today announced that Donald C. Holdsworth, a veteran international marketing executive, has been named to the Company's Board of Directors.

Mr. Holdsworth has an extensive marketing background most recently as Senior Vice President Worldwide Marketing at Merck & Co. where he was responsible for launching an industry record five major new products in one year. Previously, he held senior management positions at PepsiCo Inc. Mr. Holdsworth is a former partner with the consulting firm of McKinsey & Co. serving clients in Europe, Australia and the United States. He holds an MA from Cambridge University.

Kenneth M. Borow, M.D., President and Chief Medical Officer of Covalent, said, "The addition of Don Holdsworth to our Board will further help the Company in its mission to provide clinical trial design and support to our research clients.

Mr. Holdsworth, who was previously head of Worldwide Marketing at Merck, has a knowledge and contact base that will dramatically expand Covalent's network in the international pharmaceutical market."

Mr. Holdsworth said, "The opportunity to step onto the Board of Directors at Covalent is an exciting one. With a model based on attaining contracts by supplying clients with in-depth consultative support and clinical design capabilities, Covalent has really hit on the ideal model for a contract research organization. As such, I am happy to lend my support in helping Covalent attain its goals."

Covalent Group, Inc. provides drug development services and health management solutions to pharmaceutical, biotechnology, and device manufacturers as well as managed care organizations. To aid its customers, Covalent has developed several currently available proprietary products
utilizing interactive speech recognition technology including TeleTrial(R), for use in clinical trials, and VirtualHouseCall(R), a disease assessment system.

This document contains statements of a forward-looking nature......
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext